Qin, H., Ramakrishna, S., Nguyen, S., Fountaine, T. J., Ponduri, A., Stetler-Stevenson, M., . . . Fry, T. J. (2018). Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22. Mol Ther Oncolytics.
Chicago-stil citatQin, Haiying, et al. "Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22." Mol Ther Oncolytics 2018.
MLA-referensQin, Haiying, et al. "Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22." Mol Ther Oncolytics 2018.
Varning: dessa hänvisningar är inte alltid fullständigt riktiga.